Last reviewed · How we verify
Mizollen (MIZOLASTINE)
Mizollen (generic name: MIZOLASTINE) is a mizolastine Small molecule drug developed by Sanofi. It is currently FDA-approved (first approved 1998) for Allergic rhinitis, Perennial allergic rhinitis.
At a glance
| Generic name | MIZOLASTINE |
|---|---|
| Sponsor | Sanofi |
| Drug class | mizolastine |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
- Allergic rhinitis
- Perennial allergic rhinitis
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mizollen CI brief — competitive landscape report
- Mizollen updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Mizollen
What is Mizollen?
Mizollen (MIZOLASTINE) is a mizolastine drug developed by Sanofi, indicated for Allergic rhinitis, Perennial allergic rhinitis.
What is Mizollen used for?
Mizollen is indicated for Allergic rhinitis, Perennial allergic rhinitis.
Who makes Mizollen?
Mizollen is developed and marketed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What is the generic name of Mizollen?
MIZOLASTINE is the generic (nonproprietary) name of Mizollen.
What drug class is Mizollen in?
Mizollen belongs to the mizolastine class. See all mizolastine drugs at /class/mizolastine.
When was Mizollen approved?
Mizollen was first approved on 1998.
What development phase is Mizollen in?
Mizollen is FDA-approved (marketed).
What does Mizollen target?
Mizollen targets Histamine H1 receptor and is a mizolastine.
Related
- Drug class: All mizolastine drugs
- Target: All drugs targeting Histamine H1 receptor
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Perennial allergic rhinitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing